Lactate dehydrogenase, or LDH, is a blood test that can help evaluate and monitor ovarian dysgerminoma, the most common malignant ovarian germ cell tumor. Dysgerminoma cells can release LDH, and the level may rise with larger or more active tumor burden and fall after successful treatment. LDH is useful because it is inexpensive, widely available, and can change quickly with disease activity. Its major limitation is lack of specificity: LDH is found throughout the body, so hemolysis, liver disease, muscle injury, infection, inflammation, blood disorders, and many other cancers can also raise it. A high LDH result therefore does not diagnose dysgerminoma. In a young patient with a solid ovarian mass, clinicians interpret LDH together with imaging, AFP, beta-hCG, pathology, and the clinical picture. Serial LDH is most informative when it was clearly elevated before treatment and then normalized with response.
- LDH is a common tumor marker for ovarian dysgerminoma, but it is nonspecific and can rise from many noncancer causes.
- A markedly elevated LDH in a patient with a solid ovarian mass can support suspicion for dysgerminoma, especially when other findings fit.
- LDH may reflect tumor burden and can be followed during treatment and surveillance if it was elevated at diagnosis.
- Pure dysgerminoma usually does not raise AFP; a high AFP result should prompt evaluation for a mixed germ cell tumor or another component.
- Always compare LDH with the laboratory reference range and check for sample hemolysis, which can falsely increase the result.
Table of Contents
- What LDH Measures
- Why LDH Rises in Dysgerminoma
- Understanding High and Normal LDH
- LDH With AFP and Beta-hCG
- Using LDH for Treatment and Follow-Up
- False-High Results and Limitations
- Next Steps After an Abnormal LDH
What LDH Measures
LDH is an enzyme involved in energy metabolism. It helps convert lactate and pyruvate as cells produce and use energy. Nearly every tissue contains LDH, including red blood cells, liver, heart, skeletal muscle, kidneys, lungs, and tumors.
A standard serum LDH test measures total enzyme activity in the blood. Results are usually reported in units per liter, or U/L. The normal range varies by laboratory because instruments, reagents, and reference populations differ.
LDH is not a cancer-specific molecule. It enters the bloodstream when cells turn over rapidly, are injured, or break apart. That is why LDH can be elevated in both malignant and nonmalignant conditions.
In oncology, LDH is useful when a tumor type is known to release enough enzyme that changes in the blood parallel disease activity. Ovarian dysgerminoma is one such tumor.
Historically, LDH isoenzymes were also studied. LDH exists in several molecular forms, and dysgerminoma can be associated with increases in LDH-1 and related fractions. Modern clinical practice usually relies on total LDH rather than routine isoenzyme testing because total LDH is simpler and isoenzymes rarely add enough information to change management.
The blood test is different from tumor pathology. LDH cannot determine that an ovarian mass is a dysgerminoma. Definitive diagnosis requires tissue examination, often with characteristic morphology and immunohistochemical markers such as OCT4, SALL4, and D2-40 depending on the diagnostic workup.
Why LDH Rises in Dysgerminoma
Dysgerminoma is the ovarian counterpart of seminoma in the testis. It arises from primitive germ cells and most often affects adolescents and young adults, although it can occur outside that age range.
These tumors can grow rapidly and contain many metabolically active cells. Increased LDH may result from high glycolytic activity, cell turnover, and release of enzyme from tumor tissue. Larger tumors and more extensive disease are more likely to produce substantial elevations, although the relationship is not perfect.
Clinically, a high LDH can be a valuable clue when imaging shows a large, predominantly solid ovarian mass in a young patient. Dysgerminomas often have lobulated solid tissue and prominent enhancing fibrovascular septa on imaging. LDH does not replace these findings, but it can strengthen the pattern.
The marker is especially helpful because several ovarian germ cell tumors have different serum profiles. A yolk sac tumor typically raises AFP, while choriocarcinoma and embryonal carcinoma can raise beta-hCG. Dysgerminoma is the classic ovarian germ cell tumor associated with LDH.
Some dysgerminomas contain syncytiotrophoblastic giant cells and can produce modest beta-hCG elevations. This does not automatically mean the tumor is mixed, but it must be interpreted with pathology and the full marker panel.
A normal LDH does not exclude dysgerminoma. Small or early tumors may not release enough LDH to exceed the reference limit, and individual tumor biology varies.
Dysgerminoma can also be associated with gonadal dysgenesis in a minority of patients. When age, anatomy, or pathology raises that possibility, clinicians may recommend additional genetic or endocrine evaluation. That question is separate from the LDH result, but it can influence surgical planning and long-term care.
Another useful distinction is between diagnostic suspicion and confirmed histology. Before surgery, LDH can help clinicians prioritize dysgerminoma in the differential diagnosis and prepare an appropriate germ cell tumor marker panel. After pathology is known, the same LDH result becomes a personalized disease marker that can be trended against treatment response.
Understanding High and Normal LDH
The first step is to compare the result with the upper limit of normal from the same laboratory. There is no universal U/L cutoff for dysgerminoma.
A mild increase is common and nonspecific. It can occur after strenuous exercise, with minor tissue injury, from a hemolyzed blood sample, or during many acute illnesses. A markedly high result deserves more attention but still does not identify the cause by itself.
In a patient with a suspected ovarian germ cell tumor, interpretation depends on context:
- Is there a solid ovarian mass?
- Is the patient in the typical age range for a germ cell tumor?
- Are AFP and beta-hCG normal or abnormal?
- Is the blood sample hemolyzed?
- Are liver enzymes, blood counts, or other tests pointing to a non-ovarian source?
- Is LDH falling after tumor treatment?
If LDH was very high before surgery and drops quickly afterward, that pattern supports the idea that the tumor was the major source. If LDH stays high despite apparently successful treatment, clinicians consider residual disease as well as noncancer causes.
The number itself does not provide a formal cancer stage. Staging depends on surgical and imaging findings, including whether disease is confined to an ovary or has spread to lymph nodes, peritoneal surfaces, or distant sites.
Clinicians sometimes describe LDH relative to the upper limit of normal rather than by the raw U/L value because laboratory ranges differ. A value several times the upper limit is more striking than a small isolated increase, but even a large elevation can have another cause. The interpretation becomes much stronger when the level falls in parallel with removal or shrinkage of a confirmed dysgerminoma.
LDH can correlate with tumor burden, but it is not precise enough to estimate tumor diameter or volume. A patient with a small but biologically active lesion can have a noticeable rise, while another patient with substantial disease may have only a modest elevation.
LDH With AFP and Beta-hCG
Ovarian germ cell tumors are often evaluated with a marker panel because the pattern can help narrow the likely histology before surgery and provide a baseline for monitoring.
| Marker | Common ovarian germ cell tumor association | Key interpretation point |
|---|---|---|
| LDH | Dysgerminoma | Nonspecific; often reflects tumor burden when elevated |
| AFP | Yolk sac tumor and some mixed germ cell tumors | Significant AFP elevation argues against a pure dysgerminoma |
| Beta-hCG | Choriocarcinoma, embryonal carcinoma, some mixed tumors | Can be mildly elevated in dysgerminoma with syncytiotrophoblastic cells |
A dedicated AFP test for ovarian germ cell tumors is particularly important because AFP should not be substantially elevated in pure dysgerminoma. If it is, the pathology team looks carefully for a yolk sac or other non-dysgerminomatous component.
The beta-hCG tumor marker adds different information. A mild rise can occur in a subset of dysgerminomas, but a very high level raises concern for another germ cell component or a pregnancy-related source, depending on the clinical setting.
Marker patterns are useful but not definitive. Mixed germ cell tumors can produce more than one marker, and pregnancy can complicate interpretation of hCG. The final diagnosis still comes from pathology.
Using LDH for Treatment and Follow-Up
Dysgerminoma is highly curable, including many advanced cases, because it is very sensitive to platinum-based chemotherapy. Fertility-sparing surgery is often possible in young patients when oncologically appropriate.
A pretreatment LDH value provides a useful baseline. After removal of a localized marker-producing tumor, LDH can fall quickly because the enzyme has a relatively short circulating half-life compared with some other tumor markers.
During chemotherapy for measurable disease, serial LDH can support response assessment. A consistent decline that parallels tumor shrinkage is reassuring. A plateau or renewed rise may prompt a search for persistent disease, but clinicians must first exclude noncancer causes.
After treatment, LDH can be included in surveillance when it was elevated at diagnosis. The follow-up plan also includes history, physical examination, and imaging or other markers as indicated.
The most informative trend is usually:
- clearly elevated LDH before treatment;
- normalization with successful therapy;
- stable normal values during remission;
- reproducible rise if disease recurs.
A single mildly high surveillance value should not automatically trigger a conclusion of relapse. Repeating the blood test, checking for hemolysis, and reviewing recent illness or injury can prevent unnecessary imaging and anxiety.
If LDH was normal at diagnosis, it is a poor personalized surveillance marker. The oncology team may place more weight on imaging, symptoms, and any other marker that was abnormal.
Because ovarian germ cell tumors can affect young patients, surveillance plans also consider fertility, menstrual recovery, treatment toxicities, and long-term health after chemotherapy. Marker monitoring is only one part of survivorship care.
The speed of LDH normalization can be clinically useful, but it should not be interpreted with a rigid universal timetable. The starting value, amount of tumor removed, renal and liver function, laboratory method, and any concurrent tissue injury can affect the pattern. Clinicians are usually more interested in whether the trend is moving in the expected direction and whether imaging agrees.
If LDH begins to rise during treatment while imaging is improving, the team may look for another explanation before labeling the cancer resistant. Conversely, if symptoms and imaging worsen despite a normal LDH, the marker should not delay a change in evaluation or treatment.
False-High Results and Limitations
LDH’s biggest weakness is that it is extremely nonspecific.
Hemolysis
Red blood cells contain abundant LDH. If cells rupture during or after blood collection, the serum or plasma can show an artificially high value. Laboratories often flag a hemolyzed specimen. A repeat sample may be needed before interpreting an unexpected elevation.
Liver and muscle injury
Hepatitis, liver congestion, muscle injury, strenuous exercise, and other tissue damage can raise LDH. Other laboratory values can help identify the source.
Infection and inflammation
Many acute illnesses increase cell turnover and can cause mild or moderate LDH elevation.
Blood disorders
Hemolytic anemia and some hematologic cancers can produce substantial LDH increases.
Other cancers
LDH can rise in many malignancies, especially when tumor burden is high. It is not specific to the ovary or to germ cell tumors.
No universal dysgerminoma cutoff
The upper reference limit differs among laboratories, and published studies use different thresholds. Interpretation should focus on the local range and patient-specific trend.
Normal LDH does not rule out disease
A marker-negative dysgerminoma is possible. Suspicious imaging or symptoms require proper evaluation even when LDH is normal.
For these reasons, LDH should be treated as a context marker, not a cancer detector.
Pre-analytic quality deserves special attention because hemolysis is common and can change management if overlooked. If the specimen is flagged as hemolyzed and the LDH result is unexpected, repeating the blood draw before ordering extensive cancer imaging can be appropriate. The repeat should be interpreted together with a complete blood count, liver tests, and symptoms when another source of tissue injury is possible.
Next Steps After an Abnormal LDH
If LDH is high in a patient with an ovarian mass, the clinician first checks whether the result is technically reliable. A hemolysis flag, difficult blood draw, recent strenuous exercise, infection, or liver abnormality can offer an alternate explanation.
When a germ cell tumor is possible, AFP and beta-hCG are usually reviewed alongside LDH. Pelvic ultrasound and often CT or MRI help define the mass and look for spread.
Surgery provides the definitive diagnosis. In young patients, surgeons often aim to preserve the uterus and unaffected ovary when safe because dysgerminoma is highly curable and fertility preservation is an important goal.
If pathology confirms dysgerminoma, stage and surgical findings guide whether observation or chemotherapy is appropriate. Advanced or higher-risk disease can still have an excellent chance of cure with modern platinum-based regimens.
During follow-up, compare LDH with the patient’s original baseline rather than focusing only on whether the value is slightly above normal. A sharp rise from a stable baseline is more concerning than a minor fluctuation around the laboratory cutoff.
A broader ovarian cancer biomarker profile is not a substitute for germ cell tumor-specific markers. HE4, ROMA, and HRD testing primarily address epithelial ovarian cancers, while LDH, AFP, and beta-hCG are selected according to germ cell histology.
Patients should contact their oncology team for new abdominal or pelvic pain, rapidly increasing abdominal size, a new mass, persistent nausea or vomiting, unexplained weight loss, or other concerning changes. A normal LDH should never delay evaluation of symptoms.
Keeping a record of LDH, AFP, and beta-hCG values with dates and treatment milestones can make follow-up easier, especially when care spans several institutions. The most informative surveillance question is not simply whether LDH is above the laboratory limit, but whether it is changing in the same way it did when the known tumor was active.
LDH is most useful when its behavior is interpreted beside the tumor’s other features. Dysgerminoma can raise LDH substantially, but some patients have only modest elevations or normal values. Other ovarian germ cell tumors may instead produce AFP or beta-hCG, and mixed tumors can produce more than one marker. For that reason, a complete germ cell tumor marker panel is more informative than LDH alone.
If LDH rises during surveillance, clinicians usually confirm the laboratory result and look for alternative causes before attributing it to recurrence. Hemolyzed blood samples, liver injury, muscle damage, infection, and hematologic disease can all increase LDH. A persistent rise that parallels imaging or symptoms is more meaningful than one isolated abnormal value.
References
- Ovarian Tumor Biomarkers: Correlation Between Tumor Type and Marker Expression, and Their Role in Guiding Therapeutic Strategies. 2025 (Review)
- Dysgerminoma of the ovary 2024 (Review)
- Malignant ovarian and testicular germ cell tumors: Common characteristics but different prognoses 2024 (Review)
- Management of recurrent and persistent malignant ovarian germ cell tumors: a narrative review 2024 (Review)
- Ovarian dysgerminoma: clues to the radiological diagnosis 2023 (Review)
- Ovarian germinoma (dysgerminoma) with elevated serum lactic dehydrogenase: case report and review of literature 1982 (Review)
Disclaimer
LDH is a nonspecific blood marker that can support dysgerminoma evaluation and monitoring but cannot diagnose ovarian cancer by itself. High values can result from hemolysis, liver or muscle injury, infection, blood disorders, and many other conditions. Germ cell tumor assessment should combine LDH with AFP, beta-hCG, imaging, pathology, and the patient’s clinical history.
